Arbutus Biopharma Corporation (NASDAQ: ABUS) started the day on September 16, 2021, with a price increase of 2.13% at $4.31. During the day, the stock rose to $4.355 and sunk to $4.15 before settling in for the price of $4.22 at the close. Taking a more long-term approach, ABUS posted a 52-week range of $2.43-$5.87.
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -21.60%. Meanwhile, its Annual Earning per share during the time was 6.20%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 65.40%. This publicly-traded company’s shares outstanding now amounts to $96.87 million, simultaneously with a float of $80.17 million. The organization now has a market capitalization sitting at $377.69 million. At the time of writing, stock’s 50-day Moving Average stood at $3.14, while the 200-day Moving Average is $3.44.
While finding the extent of efficiency of the company that is accounted for 78 employees. It has generated 88,641 per worker during the last fiscal year. Meanwhile, its income per employee was -817,244. The stock had 5.50 Receivables turnover and 0.06 Total Asset turnover. For the Profitability, stocks operating margin was -828.30 and Pretax Margin of -885.16.
Arbutus Biopharma Corporation (ABUS) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Arbutus Biopharma Corporation’s current insider ownership accounts for 19.15%, in contrast to 31.70% institutional ownership. According to the most recent insider trade that took place on Feb 09, this organization’s Chief Business Officer sold 20,000 shares at the rate of 5.00, making the entire transaction reach 100,000 in total value, affecting insider ownership by 1,307,457. Preceding that transaction, on Dec 14, Company’s Chief Business Officer sold 40,000 for 5.00, making the whole transaction’s value amount to 200,032. This particular insider is now the holder of 1,327,457 in total.
Arbutus Biopharma Corporation (ABUS) Earnings and Revenue Records
In the latest quarterly report released, which was put into the public domain on 6/29/2021, the organization reported -$0.23 earnings per share (EPS) for the three months, lower than the consensus estimate (set at -$0.22) by -$0.01. This company achieved a net margin of -921.97 while generating a return on equity of -72.97. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.22 per share during the current fiscal year.
Arbutus Biopharma Corporation’s EPS increase for this current 12-month fiscal period is 65.40% and is forecasted to reach -0.79 in the upcoming year.
Arbutus Biopharma Corporation (NASDAQ: ABUS) Trading Performance Indicators
Let’s observe the current performance indicators for Arbutus Biopharma Corporation (ABUS). It’s Quick Ratio in the last reported quarter now stands at 9.40. The Stock has managed to achieve an average true range (ATR) of 0.24. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 44.96.
In the same vein, ABUS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.95, a figure that is expected to reach -0.24 in the next quarter, and analysts are predicting that it will be -0.79 at the market close of one year from today.
Technical Analysis of Arbutus Biopharma Corporation (ABUS)
If we take a close look at the recent performances of Arbutus Biopharma Corporation (NASDAQ: ABUS), its last 5-days Average volume was 7.74 million that shows progress from its year to date volume of 2.1 million. During the previous 9 days, stock’s Stochastic %D was recorded 69.63% While, its Average True Range was 0.25.
Raw Stochastic average of Arbutus Biopharma Corporation (ABUS) in the period of the previous 100 days is set at 83.93%, which indicates a major rise in contrast to 75.00% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 75.50% that was higher than 68.84% volatility it exhibited in the past 100-days period.